SAN ANTONIO – StemBioSys Inc. announced today that they have co-authored a paper which has been published in the peer reviewed journal Acta Biomaterialia on an innovative use of its technology. The company also announced expansion of their product offerings and outlined its product development plans for 2019.

The paper that was recently published in Acta Biomaterialia described how a new version of the company’s core matrix technology supports the expansion of large numbers of human articular chondrocytes while maintaining important characteristics of these cells.

The underlying research project was conducted in collaboration with the New Jersey Center for Biomaterials at Rutgers University (NJCBM) under the leadership of Dr. Joachim Kohn. Dr. Yong Mao, also from the NJCBM, was instrumental in working with SBS researchers on this study. StemBioSys President & CEO, Bob Hutchens, noted that this was the first publication that described a use of the company’s proprietary technology for articular chondrocytes. Hutchens further explained that the work is distinctive because chondrocytes are the regenerative cells for cartilage tissue.

“As our population ages, the number of people who may need cartilage tissue repair increases dramatically,” Hutchens said. “Our technology might ultimately be used in these cartilage repair treatments for patients.”

He noted that there is still much work to be done before this technology can benefit human patients. As a first step toward developing this technology, the company has submitted a government grant application to support further development of the methods and technology.

“The publication in Acta Biomaterialia is important because it provides confirmation that our science is valid and our technology has meaningful therapeutic applications” explained Dr. Sy Griffey, the company’s Chief Operating Officer. “We are looking forward to continuing our work – ideally with government support”.

Separately, the company announced that over the last several months it has introduced four new cell products into the research market. These cells have been isolated and expanded using StemBioSys’ platform matrix technology, thereby differentiating them from similar stem cells available to the research market. Three of the cell products are stem cells from various human tissue sources. The company also announced a chondrocyte cell product to support researchers doing work in cartilage repair. Hutchens noted that early sales of these cells to researchers have been very encouraging.

Finally, the company announced today that it plans to more than double its product offerings over the next 12 months.

”Today, we have seven different products on the market,” Hutchens said. “We are on track to have an additional nine products on the market by the end of 2019. It is going to be an exciting year for StemBioSys.”

StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful cell therapies. StemBioSys markets its products to the global research community under the CELLvo™ brand name.